Richard C. Frank

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz et al. · Blood · 2001 · 427 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma

Craig H. Moskowitz, Joseph R. Bertino, Jill R. Glassman et al. · Journal of Clinical Oncology · 1999 · 303 citations

Medicine, Hematology, Oncology +14

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Fiona Blackhall, Maciej Krzakowski et al. · Journal of Clinical Oncology · 2012 · 266 citations · Full text

Medicine, Oncology, Pharmacology +17

The serum-inducible mouse gene Krox-24 encodes a sequence-specific transcriptional activator.

Patrick Lemaire, Christine Vesque, J. Schmitt et al. · Molecular and Cellular Biology · 1990 · 251 citations · Full text

Life Sciences, Genetics, Molecular Biology +10

The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.

Richard C. Frank, J Zhang, Hideo Uchida et al. · PubMed · 1995 · 209 citations

Life Sciences, Genetics, Molecular Biology +14